^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fosmanogepix (APX001)

    i
    Other names: APX001, PF-07842805, APX-001, APX 001, E1211
    Associations

    News

    Trials
    Company:
    Basilea, Pfizer
    Drug class:
    GWT1 protein inhibitor
    Associations

    News

    Trials
    3ms
    A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function. (clinicaltrials.gov)
    P1, N=28, Completed, Basilea Pharmaceutica | Recruiting --> Completed
    Trial completion
    |
    fosmanogepix (APX001)
    6ms
    A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function. (clinicaltrials.gov)
    P1, N=30, Recruiting, Basilea Pharmaceutica | Active, not recruiting --> Recruiting
    Enrollment open
    |
    fosmanogepix (APX001)
    6ms
    Candidemia: An Update on Epidemiology, Risk Factors, Diagnosis, Susceptibility, and Treatment. (PubMed, Pathogens)
    Regarding treatment, the use of micafungin and anidulafungin in patients with obesity defined by a BMI > 30 kg/m2 has shown higher survival rates and therapeutic success. Meanwhile, newer antifungals such as rezafungin and fosmanogepix have demonstrated excellent results in the treatment of these patients. Therefore, this review aims to update the epidemiology and risk factors of candidemia, as well as analyze the diagnostic tools and treatments currently available.
    Review • Journal
    |
    CRP (C-reactive protein)
    |
    fosmanogepix (APX001)
    7ms
    A Study of Fosmanogepix in Healthy Adult Chinese Subjects (clinicaltrials.gov)
    P1, N=54, Completed, Basilea Pharmaceutica | Active, not recruiting --> Completed
    Trial completion
    |
    fosmanogepix (APX001)
    7ms
    A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections. (clinicaltrials.gov)
    P3, N=219, Recruiting, Basilea Pharmaceutica | Not yet recruiting --> Recruiting
    Enrollment open
    |
    fosmanogepix (APX001)
    8ms
    A Study of Fosmanogepix in Healthy Adult Chinese Subjects (clinicaltrials.gov)
    P1, N=54, Active, not recruiting, Basilea Pharmaceutica | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    fosmanogepix (APX001)
    8ms
    A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function. (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, Basilea Pharmaceutica | Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Dec 2025 | Trial primary completion date: May 2025 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    fosmanogepix (APX001)
    10ms
    A Study of Fosmanogepix in Healthy Adult Chinese Subjects (clinicaltrials.gov)
    P1, N=52, Recruiting, Basilea Pharmaceutica
    New P1 trial
    |
    fosmanogepix (APX001)
    10ms
    A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections. (clinicaltrials.gov)
    P3, N=219, Not yet recruiting, Basilea Pharmaceutica
    New P3 trial
    |
    fosmanogepix (APX001)
    12ms
    A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function. (clinicaltrials.gov)
    P1, N=24, Recruiting, Basilea Pharmaceutica | Trial primary completion date: Feb 2025 --> May 2025
    Trial primary completion date
    |
    fosmanogepix (APX001)
    1year
    A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. (clinicaltrials.gov)
    P3, N=450, Recruiting, Basilea Pharmaceutica | Not yet recruiting --> Recruiting
    Enrollment open
    |
    fosmanogepix (APX001)
    1year
    A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function. (clinicaltrials.gov)
    P1, N=24, Recruiting, Basilea Pharmaceutica | Trial completion date: Dec 2024 --> Mar 2025
    Trial completion date
    |
    fosmanogepix (APX001)